Teachers Advisors LLC decreased its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 51.7% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 13,179 shares of the company’s stock after selling 14,092 shares during the period. Teachers Advisors LLC’s holdings in Medpace Holdings were worth $382,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other large investors have also recently bought and sold shares of the stock. Alliancebernstein L.P. purchased a new stake in Medpace Holdings during the second quarter valued at approximately $476,000. Prudential Financial Inc. lifted its position in Medpace Holdings by 138.2% during the second quarter. Prudential Financial Inc. now owns 81,870 shares of the company’s stock valued at $2,374,000 after acquiring an additional 47,500 shares during the last quarter. Virginia Retirement Systems ET AL purchased a new stake in Medpace Holdings during the second quarter valued at approximately $653,000. Federated Investors Inc. PA lifted its position in Medpace Holdings by 3.1% during the second quarter. Federated Investors Inc. PA now owns 184,469 shares of the company’s stock valued at $5,350,000 after acquiring an additional 5,554 shares during the last quarter. Finally, Bernzott Capital Advisors lifted its position in Medpace Holdings by 141.4% during the second quarter. Bernzott Capital Advisors now owns 593,840 shares of the company’s stock valued at $17,221,000 after acquiring an additional 347,804 shares during the last quarter. 17.62% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: “Teachers Advisors LLC Lowers Stake in Medpace Holdings, Inc. (MEDP)” was originally reported by Week Herald and is the property of of Week Herald. If you are accessing this piece on another website, it was illegally copied and republished in violation of international copyright & trademark laws. The original version of this piece can be accessed at https://weekherald.com/2017/11/15/teachers-advisors-llc-lowers-stake-in-medpace-holdings-inc-medp.html.
A number of research firms recently commented on MEDP. Zacks Investment Research cut shares of Medpace Holdings from a “buy” rating to a “hold” rating in a research report on Tuesday. Jefferies Group LLC increased their target price on shares of Medpace Holdings from $34.00 to $38.00 and gave the company a “hold” rating in a research report on Wednesday, November 1st. William Blair cut shares of Medpace Holdings from an “outperform” rating to a “market perform” rating in a research report on Wednesday, November 1st. They noted that the move was a valuation call. Robert W. Baird increased their target price on shares of Medpace Holdings from $32.00 to $35.00 and gave the company a “neutral” rating in a research report on Tuesday, October 31st. Finally, KeyCorp reissued a “hold” rating on shares of Medpace Holdings in a research report on Tuesday, October 17th. Eight research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $36.60.
Medpace Holdings, Inc. (NASDAQ:MEDP) opened at $34.12 on Wednesday. The stock has a market cap of $1,293.28, a price-to-earnings ratio of 23.40, a price-to-earnings-growth ratio of 1.76 and a beta of -0.34. Medpace Holdings, Inc. has a fifty-two week low of $21.76 and a fifty-two week high of $39.64. The company has a quick ratio of 0.68, a current ratio of 0.68 and a debt-to-equity ratio of 0.36.
Medpace Holdings (NASDAQ:MEDP) last posted its quarterly earnings results on Monday, October 30th. The company reported $0.40 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.36 by $0.04. The business had revenue of $98.68 million during the quarter, compared to analysts’ expectations of $96.84 million. Medpace Holdings had a net margin of 6.44% and a return on equity of 10.00%. The business’s quarterly revenue was up 4.1% on a year-over-year basis. During the same quarter last year, the company posted $0.40 earnings per share. sell-side analysts expect that Medpace Holdings, Inc. will post 1.5 EPS for the current year.
In other Medpace Holdings news, major shareholder Medpace Limited Partnership sold 2,000,000 shares of the firm’s stock in a transaction on Tuesday, August 22nd. The shares were sold at an average price of $30.27, for a total value of $60,540,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 25.80% of the company’s stock.
Medpace Holdings Profile
Medpace Holdings, Inc is a clinical contract research organization. The Company provides clinical research-based drug and medical device development services. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support.
Receive News & Ratings for Medpace Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.